London Startup Set to Trial Groundbreaking Drug That Could Make Cancer Immunotherapy Safer
A London-based pharmaceutical startup is on the verge of launching a clinical trial at six NHS hospitals for a drug that could eliminate one of the most feared and life-threatening side-effects of cancer immunotherapy. Poolbeg Pharma, the company behind the initiative, believes its oral drug POLB 001 could transform how blood cancer is treated by preventing a dangerous immune reaction known as cytokine release syndrome — commonly referred to as a "cytokine storm."
This development marks a significant moment not just for oncology, but for the broader landscape of immunotherapy research in the United Kingdom. If successful, the trial could offer millions of cancer patients a safer path through treatment — one that does not carry the terrifying risk of the body's own immune system turning against itself.
What Is Cytokine Release Syndrome and Why Does It Matter?
To understand why this trial is so important, it helps to know what cytokine release syndrome actually is. When a patient undergoes cancer immunotherapy — a treatment designed to harness the immune system's natural power to fight cancer cells — there is a risk that the immune response becomes dangerously overactive. Instead of targeting only the cancer, the immune system floods the body with signalling proteins called cytokines, triggering widespread inflammation.
This reaction, often described as the immune system "going into overdrive," can lead to serious organ damage, including damage to the heart, lungs, liver, and kidneys. In severe cases, cytokine release syndrome can be fatal. For many patients, the threat of CRS is a significant barrier to accessing otherwise promising immunotherapy treatments, particularly CAR-T cell therapy and other advanced blood cancer therapies.
Current management strategies for CRS rely on treating the syndrome after it has already developed, using immunosuppressant drugs such as tocilizumab. The medical community has long been searching for a preventive approach — a way to stop the cytokine storm before it begins. That is precisely what Poolbeg Pharma's POLB 001 aims to do.
POLB 001: An Oral Drug Designed to Prevent the Storm Before It Starts
POLB 001 is an oral anti-inflammatory drug developed specifically to intercept the immune cascade responsible for cytokine release syndrome. Unlike intravenous interventions used after the fact, an oral preventive drug would be far easier to administer and could be integrated into pre-treatment protocols without adding significant complexity for clinical teams or patients.
Poolbeg Pharma has stated that POLB 001 works by modulating the immune response in a way that reduces the excessive release of pro-inflammatory cytokines while still allowing the immunotherapy to do its job against cancer cells. This balance — allowing the therapeutic immune response while dampening the harmful overreaction — is the critical challenge the drug seeks to solve.
The upcoming trial across six NHS hospitals will be a pivotal test of the drug's safety and efficacy in a real-world clinical environment. Patients receiving immunotherapy for blood cancers will be closely monitored to assess whether POLB 001 reduces the incidence and severity of CRS compared to standard care.
Why This Trial Is a Major Step Forward for NHS Oncology
Running this trial through the NHS gives the study immediate credibility and scale. The NHS treats thousands of blood cancer patients each year, and the infrastructure of six hospital sites means the trial can recruit a meaningfully diverse patient population within a robust healthcare setting. Positive results from an NHS-based trial would also carry significant weight when it comes to potential future approval and adoption within UK healthcare — and likely internationally.
For clinicians working in haematology and oncology wards, a preventive drug for CRS would be a practical game-changer. It could allow more patients to be considered eligible for immunotherapy in the first place, reduce the burden of intensive care admissions linked to severe CRS, and potentially improve overall survival outcomes by enabling patients to complete their full course of treatment without life-threatening interruptions.
Poolbeg Pharma's Broader Ambitions: A GLP-1 Weight Loss Pill in Development
Beyond the CRS trial, Poolbeg Pharma has revealed that it is also working on a GLP-1 receptor agonist in pill form — entering one of the most commercially competitive and scientifically exciting spaces in modern pharmaceuticals. GLP-1 drugs, which include well-known injectable medications used for weight loss and type 2 diabetes management, have transformed endocrinology in recent years. An oral version could dramatically expand patient access, given that many people are reluctant to self-administer injections.
The company's simultaneous pursuit of an anti-CRS drug and a GLP-1 pill suggests an ambitious pipeline strategy, positioning Poolbeg Pharma as a startup willing to tackle some of the most consequential unmet medical needs of the decade.
The Bigger Picture: Unlocking the Full Potential of Immunotherapy
Cancer immunotherapy has been one of the most exciting medical advances of the past two decades. Treatments that once seemed impossible — training a patient's own immune cells to hunt and destroy tumours — are now standard care for several cancer types. Yet the field's continued evolution has been partly constrained by the side-effect profile of these powerful treatments.
Cytokine release syndrome sits near the top of that list of concerns. A drug that reliably prevents it would not only protect patients but could also unlock access to immunotherapy for people who are currently considered too frail or too high-risk to receive it safely.
- It could expand the pool of eligible patients for CAR-T and other advanced immunotherapies.
- It could reduce hospitalisation rates and associated costs within health systems like the NHS.
- It could improve quality of life for patients undergoing cancer treatment by reducing the anxiety and physical toll associated with severe immune reactions.
- It could accelerate the development of next-generation immunotherapy combinations that are currently limited by CRS risk.
What Comes Next for Poolbeg Pharma and the POLB 001 Trial
As the trial gets underway at NHS hospital sites, the medical community will be watching closely. Early-phase results will help determine whether the drug's mechanism translates safely into human subjects and whether the dosing strategy is effective in a clinical setting. If initial findings are encouraging, the path toward larger Phase II and Phase III trials — and ultimately regulatory submission — could move quickly given the clear unmet medical need.
Poolbeg Pharma's work represents exactly the kind of innovation that the UK's life sciences sector needs to sustain its global reputation. By tackling a problem at the intersection of patient safety and treatment efficacy, and doing so through NHS collaboration, the company is demonstrating that London remains a serious hub for pharmaceutical research and development.
For patients living with blood cancer, and for the clinicians who treat them, the prospect of a simple oral drug that prevents a cytokine storm is not just scientifically interesting — it is deeply hopeful.